Dianthus Therapeutics (DNTH) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $135.00 price target on the stock.
Wedbush Keeps Outperform on Dianthus Therapeutics, Inc. (DNTH), Highlights Potential of Claseprubart in CIDP [Yahoo! Finance]
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit [Yahoo! Finance]
Dianthus Therapeutics (DNTH) had its "outperform" rating reaffirmed by William Blair.
Dianthus Therapeutics Hits Early “Go” in CAPTIVATE Phase 3 CIDP Trial, Drops 600 mg Arm [Yahoo! Finance]